💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Lincoln Pharmaceuticals Limited is engaged in the business of manufacturing and trading pharmaceutical products, as well as undertaking contract manufacturing from pharmaceuticals companies across India and the globe. The Company’s product categories include tablets,…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, slow-growing business, trading cheap versus its own history.
Lincoln Pharma is scored on the pharma / healthcare framework. It keeps a healthy 12.5% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.21× reported profit. Free cash flow is worth about 0.8% of its market value.
Over the last 3 years revenue compounded at 10%/yr and profit at 6%/yr. Book value has grown 15%/yr. Return on equity is a modest 11.9%. In the latest quarter profit fell 44% versus the prior quarter.
At 12× earnings, the stock sits at the 12th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price asks for only ~0%/yr growth over a decade — undemanding expectations. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 10.49 | — | — |
| P/B | 1.25 | 4.1 | better |
| EV/EBITDA | 6.91 | 19.33 | better |
| ROE | 11.94 | — | — |
| ROCE | 15.72 | 14.41 | better |
| ROA | 10.05 | — | — |
| Quick Ratio | 4.53 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 10% CAGR — growing but slowly.
Revenue is outpacing profit (10% vs 6%) — costs are rising faster than the top line.
Operating margin has compressed from 19% to 16% — costs or competition are eating into profitability.
ROE at 12% — modest; the capital isn't working hard.
6% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.2× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Low quarterly variance (10% spread) — a predictable, non-seasonal revenue stream. Run-rate stepping up — recent quarters average 10% above earlier ones.
Profit fell 44% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly margins are compressing (16% → 10%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 49.8% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.